PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Novartis’ Cosentyx reduces synovitis in new psoriatic arthritis study

Novartis’ interleukin-17A (IL-17A) Cosentyx (secukinumab) demonstrated early synovitis reduction in patients with active psoriatic arthritis in the phase IIIb ULTIMATE study.

Synovitis, or joint lining inflammation, was assessed using Power Doppler ultrasonography (PDUS), an advanced and sensitive imaging technique.

The primary endpoint, which used a standardised ultrasound synovitis score (GLOESS), showed objectively significant benefit of Cosentyx compared to placebo on synovitis at week 12, with early improvement observed from week one, according to Novartis.

Cosentyx treatment also significantly improved key second endpoints versus placebo, the Swiss pharma company added.

In psoriatic arthritis (PsA), synovitis can lead to joint damage and if left untreated, this damage can be irreversible.

In addition to reducing synovitis, Cosentyx has previously been shown to provide long-lasting inhibition of radiographic progression in PsA, limiting joint damage and helping to improve outcomes for patients.

“As a strong believer in the diagnostic and treatment monitoring benefits of ultrasound, this first large randomised double-blind placebo-controlled clinical trial in PsA with an ultrasonographic primary endpoint is incredibly exciting,” said Catherine Bakewell of the Intermountain Medical Group and an investigator in the ULTIMATE study.

“The ability to use a sensitive imaging technique to assess synovitis and enthesitis in PsA represents a breakthrough in how we conceptualise treatment goals,” she added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026